Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.
For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.
For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $90M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Valence Li... | valencefun... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.09.2021 | - | $90M | - |
Mentions in press and media 22
| Date | Title | Description |
| 12.11.2025 | - | CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury... |
| 16.03.2023 | Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 | DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. LPTX, a biotechnology company focused on developing targeted and... |
| 18.01.2023 | Leap Therapeutics Acquires Flame Biosciences | Leap Therapeutics, Inc. (Nasdaq: LPTX), a Cambridge, MA-based biotechnology company focused on developing targeted and immuno-oncology therapeutics, is to merge with Flame Biosciences, Inc., a New Hope, Pennsylvania-based biotechnology comp... |
| 21.11.2022 | Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference | CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Offic... |
| 05.09.2022 | Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress | Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survival is... |
| 12.11.2021 | Leap Therapeutics Reports Third Quarter 2021 Financial Results - Form 8-K | Leap Therapeutics Reports Third Quarter 2021 Financial Results Cambridge, MA - November 12, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reporte... |
| 12.11.2021 | Leap Therapeutics Reports Third Quarter 2021 Financial Results | CAMBRIDGE, Mass., Nov. 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended Sep... |
| 24.09.2021 | Leap Therapeutics : Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (Form 8-K) | Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares Cambridge, MA - September 24, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX... |
| 24.09.2021 | Leap Therapeutics : Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Sept. 24, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 ... |
| 22.09.2021 | Leap Therapeutics : Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants (Form 8-K) | Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants Cambridge, MA - September 22, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncolog... |
Show more